LPL Financial’s Franklin Genomic Advancements ETF HELX Stock Holding History
Bought
Maintained
Sold
Other funds holding HELX
HI
LPL Financial's HELX Position: Q2 2026 in Review
LPL Financial increased its Franklin Genomic Advancements ETF (HELX) stake by 130% in Q2 2026, buying an estimated $302K and bringing the position to 15,404 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #4843.
LPL Financial first reported a position in HELX in Q4 2021 and has held it in 17 quarters since. 6 funds tracked by Wall St. Rank hold HELX as of Q2 2026.
- LPL Financial held 15,404 shares of Franklin Genomic Advancements ETF worth $616K as of Q2 2026.
- LPL Financial bought 8,698 Franklin Genomic Advancements ETF shares in Q2 2026, an estimated $302K.
- Franklin Genomic Advancements ETF made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4843 holding.
- LPL Financial first reported a position in Franklin Genomic Advancements ETF in Q4 2021 and has held it in 17 quarters since.
- 6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2026.
Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.